GenoCell

GenoCell is a South Korean biotechnology company specializing in the development of next-generation cell therapies for solid tumors. The company leverages its proprietary CAR-T and CAR-NK platforms to target antigens such as Mesothelin and Glypican-3, which are highly expressed in difficult-to-treat cancers like pancreatic and hepatocellular carcinoma. GenoCell aims to overcome the limitations of current cell therapies in solid tumor environments through enhanced infiltration and persistence technologies. Their pipeline includes several candidates in the pre-clinical stage moving toward IND-enabling studies. Founded by experts from Seoul National University, the company is part of a growing cluster of innovative immunotherapy firms in the region.